(Q73114890)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

title

Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

1 reference

G Rocha

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

J Deschênes

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

M Cantarovich

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 February 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

245-251

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

The value of laboratory testing in uveitis

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

The use of cyclosporine in high-risk keratoplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Down-regulation of autoantibody levels of cyclosporine and bromocriptine treatment in patients with uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Renal function and blood pressure in patients receiving long-term, low-dose cyclosporine therapy for idiopathic autoimmune uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Cyclosporin A treatment of Behçet's disease: a long-term study

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Treatment of intraocular inflammatory disease with cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Side effects of systemic cyclosporine in patients not undergoing transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Use of steroids and immunosuppressive drugs in the management of posterior uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Renal interstitial fibrosis and vascular changes. Occurrence in patients with autoimmune diseases treated with cyclosporine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Effects of cyclosporine on tubular acidification function in patients with idiopathic uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Cyclosporine plasma levels six hours after oral administration. A useful tool for monitoring therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Immunological and pharmacological monitoring in the clinical use of cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Renal histopathologic alterations in patients treated with cyclosporine for uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Renal hemodynamic effects of cyclosporine treatment in patients with chronic uveitis and normal native kidneys

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Combination low dose cyclosporin A and steroid therapy in chronic intraocular inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2897%2930328-5

7 January 2021

10.1016/S0161-6420(97)30328-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9052628%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference